# A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice

> **NCT02545465** · — · COMPLETED · sponsor: **Bayer** · enrollment: 125 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)

## Key facts

- **NCT ID:** NCT02545465
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-15
- **Primary completion:** 2016-05-31
- **Final completion:** 2016-08-31
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2017-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02545465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02545465, "A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02545465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*